Moderna and Lonza announce strategic collaboration to manufacture vaccine against Novel Coronavirus
BASEL, SWITZERLAND: Moderna Inc., a clinical stage biotechnology company, and Lonza Ltd. have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies plan to establish manufacturing suites at…